MedPath

Sertraline

Generic Name
Sertraline
Brand Names
Zoloft
Drug Type
Small Molecule
Chemical Formula
C17H17Cl2N
CAS Number
79617-96-2
Unique Ingredient Identifier
QUC7NX6WMB
Background

Sertraline is a popular antidepressant medication commonly known as a selective serotonin reuptake inhibitor (SSRI), and is similar to drugs such as Citalopram and Fluoxetine. Despite marked structural differences between compounds in this drug class, SSRIs exert similar pharmacological effects.

Several weeks of therapy with sertraline may be required before beneficial effects are noticed. Sertraline displays enhanced safety or tolerability than other classes of antidepressants, which frequently cause high levels of drowsiness, dizziness, blurred vision, and other undesirable effects.

Indication

Sertraline is indicated for the management of major depressive disorder (MDD), post-traumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD), panic disorder (PD), premenstrual dysphoric disorder (PMDD), and social anxiety disorder (SAD). Common off-label uses for sertraline include the prevention of post stroke depression, generalized anxiety disorder (GAD), fibromyalgia, premature ejaculation, migraine prophylaxis, diabetic neuropathy, and neurocardiogenic syncope.

Associated Conditions
Binge Eating Disorder (BED), Bulimia Nervosa, Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD), Panic Disorder, Post Traumatic Stress Disorder (PTSD), Premenstrual Dysphoric Disorder (PMDD), Social Anxiety Disorder (SAD)

Effects of Sertraline on Brain Connectivity in Adolescents With OCD

Phase 1
Completed
Conditions
OCD
Interventions
Other: No Intervention
First Posted Date
2016-06-13
Last Posted Date
2021-01-05
Lead Sponsor
University of Minnesota
Target Recruit Count
41
Registration Number
NCT02797808
Locations
🇺🇸

University of Minnesota, Minneapolis, Minnesota, United States

Stress & Premenstrual Symptoms Study

Phase 4
Completed
Conditions
PMDD
Stress
Mood
Interventions
First Posted Date
2016-05-19
Last Posted Date
2022-11-17
Lead Sponsor
Johns Hopkins University
Target Recruit Count
84
Registration Number
NCT02777372
Locations
🇺🇸

Center for Women's Reproductive Mental Health, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States

A Proof-of-concept Clinical Trial Assessing the Safety of the Coordinated Undermining of Survival Paths by 9 Repurposed Drugs Combined With Metronomic Temozolomide (CUSP9v3 Treatment Protocol) for Recurrent Glioblastoma

First Posted Date
2016-05-12
Last Posted Date
2021-10-05
Lead Sponsor
University of Ulm
Target Recruit Count
10
Registration Number
NCT02770378
Locations
🇩🇪

University of Ulm School of Medicine, Ulm, Baden-Württemberg, Germany

A Policy Relevant US Trauma Care System Pragmatic Trial for PTSD and Comorbidity

Not Applicable
Completed
Conditions
Depression
Posttraumatic Stress Disorder
Mild Cognitive Impairment
Alcohol-Related Disorders
Substance-Related Disorders
Wounds and Injury
Suicidal Ideation
Brain Injuries
Quality of Life
Chronic Disease
Interventions
First Posted Date
2016-01-14
Last Posted Date
2021-07-02
Lead Sponsor
University of Washington
Target Recruit Count
635
Registration Number
NCT02655354
Locations
🇺🇸

Jacobi Medical Center, Bronx, New York, United States

🇺🇸

University of Rochester, Rochester, New York, United States

🇺🇸

Honor Health, Scottsdale, Arizona, United States

and more 21 locations

Study to Evaluate The Effect Of Sertraline on the Cardiac Repolarization in Healthy Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2016-01-11
Last Posted Date
2021-01-27
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Target Recruit Count
54
Registration Number
NCT02651623
Locations
🇧🇪

Pfizer Clinical Research Unit, Brussels, Belgium

A Randomized Controlled Trial of Sertraline in Paroxysmal Arterial Hypertension

Phase 4
Conditions
Hypertension
Interventions
Drug: Placebo
First Posted Date
2015-12-29
Last Posted Date
2017-09-08
Lead Sponsor
University Hospital Olomouc
Target Recruit Count
136
Registration Number
NCT02641652

Efficacy of Nepeta Menthoides Extract on Anxiety of Patients With Depression: a Double-blind Randomized Controlled Clinical Trial

Phase 2
Completed
Conditions
Depression
Anxiety
Interventions
Drug: Nepeta menthoides Boiss & Bohse freeze dried extract
First Posted Date
2015-10-01
Last Posted Date
2015-10-01
Lead Sponsor
Shiraz University of Medical Sciences
Target Recruit Count
70
Registration Number
NCT02565316

PTSD Prevention Study Examining the Efficacy of Sertraline in Burn Victims

Phase 4
Terminated
Conditions
Post-traumatic Stress Disorder
Interventions
Drug: Placebo oral capsule
First Posted Date
2015-08-13
Last Posted Date
2018-04-10
Lead Sponsor
University of Utah
Target Recruit Count
5
Registration Number
NCT02520726
Locations
🇺🇸

University of Utah Hospital, Salt Lake City, Utah, United States

Serotonin Selective Reuptake Inhibitor Treatment of Dual Diagnosis Post-traumatic Stress Disorder and Alcohol Problems

Phase 4
Completed
Conditions
PTSD
Alcohol Use Disorder
Interventions
Drug: Placebo
First Posted Date
2015-07-22
Last Posted Date
2018-04-10
Lead Sponsor
The University of Texas Health Science Center at San Antonio
Target Recruit Count
49
Registration Number
NCT02504931
Locations
🇺🇸

South Texas Veterans Health Care System, San Antonio, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath